Leading group of Baraclude generics, topped by Bukwang Pharm

Among the 62 generics entered in the market of ‘Baraclude,’ a drug expired in patent on the 10^th of October, the leading group has been clarified.

According to the UBIST’s outpatient prescription data, there were about 10 companies exceeding monthly prescriptions of KRW 10 million; among them, Bukwang Pharm’s ‘Bukwang Entecavir Tab’ recorded the highest record in prescriptions both on October ...